Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ute Hegenbart

Showing results (131-140 of 237) with videos related to

Pageof 24
Sort By:
European Journal of Haematology|October 18, 2006
Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantationJens Klaus, Doris Herrmann, Iris Breitkreutz, et al.
Annals of Hematology|March 22, 2025
Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survivalSara Oubari, Maria Papathanasiou, Lars Michel, et al.
Bone Marrow Transplantation|June 20, 2020
The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysisLorenz Selberg, Peter Stadtherr, Sascha Dietrich, et al.
Clinical Transplantation|August 6, 2013
Modified body mass index and time interval between diagnosis and operation affect survival after liver transplantation for hereditary amyloidosis: a single-center analysisClemens Franz, Katrin Hoffmann, Ulf Hinz, et al.
Cell Reports Methods|December 1, 2022
A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myelomaTobias Dittrich, Sebastian Köhrer, Martin Schorb, et al.
Ejhaem|December 5, 2022
Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior-A case reportSimone Feurstein, Julian Zoller, Constantin Schwab, et al.
British Journal of Haematology|June 2, 2020
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemicEfstathios Kastritis, Ashutosh Wechalekar, Stefan Schönland, et al.
European Journal of Haematology|May 26, 2018
CD7 is expressed on a subset of normal CD34-positive myeloid precursorsKatharina Kriegsmann, Harald Löffler, Volker Eckstein, et al.
Cytometry. Part B, Clinical Cytometry|March 27, 2018
Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myelomaKatharina Kriegsmann, Tobias Dittrich, Brigitte Neuber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2013
Reply to S. Girnius et alGiovanni Palladini, Angela Dispenzieri, Morie Gertz, et al.
Pageof 24

Showing results (131-140 of 237) with videos related to

Sort By:
Pageof 24
European Journal of Haematology|October 18, 2006
Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantationJens Klaus, Doris Herrmann, Iris Breitkreutz, et al.
Annals of Hematology|March 22, 2025
Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survivalSara Oubari, Maria Papathanasiou, Lars Michel, et al.
Bone Marrow Transplantation|June 20, 2020
The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysisLorenz Selberg, Peter Stadtherr, Sascha Dietrich, et al.
Clinical Transplantation|August 6, 2013
Modified body mass index and time interval between diagnosis and operation affect survival after liver transplantation for hereditary amyloidosis: a single-center analysisClemens Franz, Katrin Hoffmann, Ulf Hinz, et al.
Cell Reports Methods|December 1, 2022
A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myelomaTobias Dittrich, Sebastian Köhrer, Martin Schorb, et al.
Ejhaem|December 5, 2022
Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior-A case reportSimone Feurstein, Julian Zoller, Constantin Schwab, et al.
British Journal of Haematology|June 2, 2020
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemicEfstathios Kastritis, Ashutosh Wechalekar, Stefan Schönland, et al.
European Journal of Haematology|May 26, 2018
CD7 is expressed on a subset of normal CD34-positive myeloid precursorsKatharina Kriegsmann, Harald Löffler, Volker Eckstein, et al.
Cytometry. Part B, Clinical Cytometry|March 27, 2018
Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myelomaKatharina Kriegsmann, Tobias Dittrich, Brigitte Neuber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2013
Reply to S. Girnius et alGiovanni Palladini, Angela Dispenzieri, Morie Gertz, et al.
Pageof 24